Glicentin (a highly purified 100-amino-acid peptide with glucagon-like immunoreactivity from porcine gut) was subjected to limited digestion with trypsin and carboxypeptidase B, and the resulting peptides were studied by gel filtration and region-specific glucagon radioimmunoassays. Similar digests of glucagon and purified fragments of glucagon were studied in. parallel. Glicentin gave rise to peptides that corresponded closely to the 1-17 and 19-29 fragments of glucagon. Also, 125I-labelled glicentin and 125I-labelled glucagon gave rise to identical fragments after trypsin treatment. On the basis of this and other evidence [Jacobsen, .Demandt, Moody & Sundby (1977) Biochim. Biophys. Acta 493, 452-4591 it is concluded that glicentin contains the entire glucagon sequence at residues number 64-92 and thus fulfills one of the requirements for being a 'proglucagon'.
A family of peptides with glucagon-like immunoreactivity can be extracted from the intestinal mucosa of a number of vertebrate and invertebrate species including man and pig; one of the peptides is probably identical with true pancreatic glucagon (mol.wt. 3485), but the majority of the extractable immunoreactivity stems from peptides with higher mol.wt., which show immunoreactivity towards antisera directed against the mid-to N-terminal sequence of the glucagon molecule only (Holst, 1978) . One of these peptides, provisionally named 'glicentin', was purified from porcine intestine (Sundby et al., 1976) and was shown to consist of 100 amino acid residues. The sequence of its 10 C-terminal amino acids corresponds closely to the C-terminal sequence of the so-called 'proglucagon fragment' isolated by Tager & Steiner (1973) , and on the basis of this and other indirect evidence it was hypotheszied that the glicentin molecule contained the entire glucagon sequence (Jacobsen et al., 1977) .
We here report the results of immunochemical studies of the structure of glicentin, which strongly support this hypothesis.
Experimental Materials
Highly purified glicentin ('glucagon-like immunoreactivity 1') from porcine intestinal mucosa (Sundby et al., 1976; Jacobsen et al., 1977) was a generous gift from Drs. F. Sundby and A. Moody, Vol. 187 the NOVO Research Institute, Bagsvmrd, Denmark. Highly purified porcine glucagon and (monoiodinated) 12II-labelled glucagon (Jorgensen et al., 1972) and 251I-labelled glicentin (Moody et al., 1978) were also gifts from the NOVO Research Institute. Purified tryptic fragments of porcine glucagon were gifts from Dr. A. Salokangas, National Institute for Medical Research, London NW7, U.K. A synthetic peptide corresponding to the 10 C-terminal amino acids of glicentin (Jacobsen et al., 1977) Radioimmunological determination of glucagonlike immunoreactivity was performed as previously described (Holst & Aasted, 1974; Holst, 1977a,b) Antiserum 4304 binds labelled and unlabelled glucagon and glicentin with identical affinity (Holst, 1977a) , whereas antiserum 4305 does not bind intact glicentin.
The assays were modified as follows. Antiserum 4305 was used instead of the previously described antiserum 4317, because of its identical specificity and superior avidity (K for glucagon binding is 5 x 10111/mol); the assay buffer was the buffer described above for column experiments; separation was performed using plasma-coated charcoal (Stadil & Rehfeld, 1973) . Detection limits of the assays were 2-3 pM and the within-assay coefficient of variation was better than 10%. Enzymic degradations were performed at 370C
for 30-120min using trypsin at 10-100,ug/ml. When followed by a carboxypeptidase (20,ug/ml) incubation, trypsin activity was inhibited by a soya-bean trypsin inhibitor. The incubations were terminated by the addition of aprotinin (5000 kallikrein-inhibiting units at 00C), and the mixture was applied immediately to the column. Glucagon fragment 1-17 was prepared by trypsin treatment of methylmaleic anhydride-treated glucagon as described by Senyk et al. (1971) and by Dixon & Perham (1968) .
All experiments (----) antisera to glucagon, and plotted against coefficient ofdistribution, Kd (a) Glicentin (30pmol) was incubated with trypsin (lOO,ug/ml) for 120min followed by addition of soyabean trypsin inhibitor (lOO,ug/ml), and a sample was removed for gel filtration. (b) Carboxypeptidase B (20,ug/ml) was added to the remainder, and incubation was continued for a further 60min. range of 8 determinations 0.71-0.76) as determined by using antisera 4305 and 4304 which are reactive with sequences 19-29 and 6-15 respectively. Note the homogeneity of these controls, the inability of antiserum 4305 to detect immunoreactivity in intact glicentin, and the exact symmetry of the two assays of the glucagon peak.
Figs. l(b) and l(e) show the results of limited tryptic digestion (10,ug/ml, 30min, peptide/enzyme ratio approx. 1). Glucagon is now no longer homogeneous, there is a surplus of 6-15 immunoreactivity, and part of the 19-29 immunoreactivity has moved to the right. Glicentin is now markedly heterogeneous, the main peak has moved to the right, and a new peak of 6-15 immunoreactive material has appeared at Kd 0.80; simultaneously, 19-29-immunoreactive material has appeared at Kd 0.33 and atKd 0.8-0.85.
Further tryptic digestion (10-20,ug/ml for 60-120min) breaks down glucagon to one peak of immunoreactive homogeneous material at Kd 0.85, with only 19-29 immunoreactivity (Fig. 1 ) , whereas glicentin (Fig. lc) is broken down to homogeneous peaks at Kd 0.45 and 0.8, almost without 19-29 immunoreactivity. After prolonged trypsin treatment, the peak at Kd 0.8 disappears (Fig. 3a) , and, after incubation overnight with trypsin at 100,g/ml, the immunoreactivity of glicentin disappears altogether (results not shown). However, if glicentin is treated with carboxypeptidase B after limited or prolonged tryptic digestion, a large homogeneous peak containing 19-29-immunoreactive material appears at Kd 0.85 (Figs. 2a and  3) . Fig. 2(b) shows a refiltration (after freeze-drying) of the fractions collected between Kd 0.7 and 0.95 in the experiment shown in Fig. 1(b) ; the eluted immunoreactivity clearly consists of two homogeneous peaks of material, one with 6-15 immunoreactivity and a Kd of 0.80, and another with only 19-29 immunoreactivity and a Kd of 0.85. In Fig.  2(c) is shown a refiltration of similar fractions from the experiment in Fig. l(c) ; the immunoreactive material eluted in this area clearly consists of one homogeneous moiety with Kd 0.8 and exclusively 6-15 immunoreactivity. Fig. 2(d) shows the results of treatment with trypsin and carboxypeptidase B of a synthetic peptide consisting of the glucagon sequence from residue 17 to 29 plus another eight amino acids corresponding to the proposed sequence of the C-terminus of glicentin (Jacobsen et al., 1977 Fig. 2(f) shows the elution profile of glucagon fragment 1-17, which is eluted as a homogeneous peak of 6-15-immunoreactive material at Kd O.80. Fig. 4 shows the results of a series of experiments in which the elution profiles and immunoreactivities of labelled glicentin and glucagon were studied before and after trypsin treatment. In Figs. 4(a) and 4(d) are shown the radioactivity elution profiles of the intact peptides; in addition is shown the elution profile of 22Na+ used for calibration. In Figs. 4(b) and 4(e) are shown, the radioactivity elution profiles after trypsin treatment of the two peptides. Note the similarity of the two profiles, with one peak at Kd 0.90 and another at Kd 1.05. Samples of the eluted fractions were then incubated with surplus 6-15-and 19-29-immunoreactive antisera. After separation of bound and free moieties, the antibody-bound radioactivity was plotted against Kd. Again, glucagon and glicentin showed a similar pattern; in both cases a single homogeneous exclusively 6-15-immunoreactive fragment with Kd 0.90 was found. Vol. 187 341 r Discussion Our gel-filtration results have been given in terms of the coefficients of Iistribution, Kd, since this value is supposed to be relatively independent of geometry and packing density of the column (Determann, 1969) , but the Kd of a given substance still varies somewhat, and we have therefore tried to minimize all sources of variability in the column set-up (see the Experimental section); in this way the standard deviation for the Kd of glucagon was held below 0.02 Kd units. We are therefore confident that differences of 0.05 Kd unit are highly significant and are caused by true differences in hydrodynamic volumes of the eluted molecules. On the basis of these considerations we offer the following interpretation of our results.
Glucagon (Fig. 5) contains lysine or arginine residues at positions 12, 17 and 18, and is therefore susceptible to tryptic cleavage at these sites; limited tryptic digestion of glucagon could therefore lead to the formation of a mixture of the following peptides: 1-12, 1-17(18), 13-17(18), 13-29 and 18(19)-29. Of these, our 5-16-immunoreactive antiserum (4304) will react with peptide 1-17 (18) (Fig. 6) .
The synthetic peptide consisting of glucagon 17-29 plus the C-terminal sequence of glicentin (see Fig. 5 ) could not be measured by either antiserum; this shows that the C-terminal sequence of glucagon must be free in order to be measurable by 19-29-immunoreactive antisera. Tryptic digestion should not lead to the formation of measurable fragments, in agreement with our negative findings. A combination of trypsin and carboxypeptidase B treatment, however, should lead to the formation of a measurable 19-29 peptide, and this was also found (Fig. 2d) .
The radioactive label 1251 is uniformly distributed between the two tyrosine residues in mono-iodinated glucagon (von Schenck & Jeppsson, 1977) . By trypsin treatment, again assuming that the 12-13 bond is less susceptible than the 17-19 bonds, labelled glucagon should give rise to the following radioactive fragments: 1-12, 1-17(18), 13-17(18) and 13-29; of these the 13-17(18) fragment, because of the iodine and its size, would be expected to be eluted at Kd 2 1.0. Of these fragments, only 1-17(18) and 13-29 would be expected to be immunoreactive. In our experiments radioactivity was eluted at Kd 0.9 and 1.05, but only the peak at Kd 0.90 was immunoreactive, and, as expected, NH2-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ls-Tyr-Leu-Asp-Ser-Ag-Arg-Ala- displayed 5-16 immunoreactivity. The peak at Kd 0.90 must therefore represent labelled 1-17(18) glucagon, and the peak at Kd 1.05 the 13-17(18) fragment; labelled fragment 13-29 was not found (since the 19-29-immunoreactive antiserum would be expected to bind such a fragment).
Upon trypsin treatment, glicentin gave rise to immunoreactive fragments which were remarkably similar to those of glucagon digestion. If the proposed sequence of its 37 C-terminal amino acids is correct (Fig. 5 ), extensive trypsin treatment should lead to complete disappearance of immunoreactivity, since the 19-30 fragment formed (Fig. 5b) would be immeasurable (cf. the experiments with the synthetic '17-37' peptide); this was also found. Limited trypsin treatment should lead to the formation of immunoreactive 1-17(18) glucagon, and such a peptide was indeed formed (Fig. lb and Fig.  2b) ; in some experiments small amounts of a peptide corresponding to the 19-29 fragment were also formed as shown in Figs. 1 and 2(b) ; how this peptide is formed is not clear. On the other hand, a combination of trypsin and carboxypeptidase B treatment should lead to the formation of a clearly distinguishable peak of 19-29 fragment; this was also the case (Figs. 2a and 3 ). Labelled glicentin gave rise to radioactive, as well as immunoreactive, fragments which correspond closely to those obtained from labelled glucagon (Fig. 4) .
In conclusion, our results strongly suggest that glicentin contains sequences corresponding to the glucagon sequences 1-17(18) and 18(19)-29; on the basis of this evidence it is tempting to conclude that glicentin contains the entire glucagon sequence.
The importance of this assumption is obvious; glicentin is extracted from porcine intestinal mucosa, but glicentin-like immunoreactivity has recently been demonstrated in the pancreatic A-cells of several species (Ravazzola et al., 1979) . It has therefore been proposed that glicentin is the proper proglucagon (Moody et al., 1978) ; this hypothesis gains considerable support from the present results.
